The landscape of American primary care is undergoing a seismic shift as private equity firms increasingly pivot toward membership-based models, including Concierge medicine and Direct Primary Care (DPC). While the "entry story"—the initial acquisition and infusion of capital—has been widely documented and celebrated by proponents of market-driven healthcare, the "exit story" remains largely untold. As multi-billion-dollar firms like Goldman Sachs, Charlesbank, and Revelstoke deepen their stakes in these models, the long-term stability of the patient-physician relationship faces an unprecedented and currently unpriced risk. The transition from independent practice to private equity ownership typically follows a predictable cycle of aggressive scaling followed by a secondary buyout, a process that may fundamentally conflict with the core value proposition of direct care: continuity and trust.
The Economics of the Entry: Why Private Equity Targets Direct Care
Private equity (PE) firms typically operate on a fund-based model, holding physician practices for three to eight years before seeking a return on investment through a sale. In the broader healthcare sector, more than half of these practices are resold within three years of the initial investment. The attraction to Concierge and DPC models lies in their revenue structure. Unlike traditional fee-for-service models, which rely on procedural billing and are subject to the whims of insurance reimbursement rates, membership-based models provide a steady, predictable cash flow.
This recurring revenue is highly attractive to investors seeking "EBITDA" (Earnings Before Interest, Taxes, Depreciation, and Amortization) stability. However, the incentive to scale aggressively before an exit does not depend on how the revenue is generated; it depends on whether increased size leads to a higher valuation multiple. This mechanism, known as "multiple arbitrage," is the engine of the PE thesis. A firm acquires a "platform" practice and then "bolts on" smaller practices that trade at lower valuation multiples. By combining these into a larger, unified network, the firm creates an entity that can command a multiple of 12 to 14 times EBITDA or more upon exit. The profit is derived not necessarily from improved clinical outcomes, but from the delta between the assembly cost and the final sale price of the consolidated platform.
A Chronology of Consolidation in the Direct Care Market
The timeline of private equity involvement in direct care shows a steady progression from niche experimentation to large-scale infrastructure building. Understanding the sequence of these investments reveals how the market has matured and where the pressure points are forming.
- 2014 – The MDVIP Acquisition: Goldman Sachs and Charlesbank Capital Partners acquired MDVIP, a leader in the concierge medicine space. This move signaled that the concierge model, once seen as a luxury service, had the scalability required for institutional investment. MDVIP has maintained a patient satisfaction rate above 97% and has remained under the same ownership for over a decade, representing a rare "long hold" in the PE world.
- 2018 – The Rise of Advanced Primary Care: OMERS Private Equity acquired Premise Health, a leading provider of employer-sponsored health centers. This marked a shift toward "Advanced Primary Care" (APC), where large employers bypass traditional insurance networks to provide direct care to employees.
- 2020-2024 – The Infrastructure Boom: Firms like Revelstoke and Frontier began building employer-facing DPC infrastructure. These firms are not just buying individual clinics; they are building the digital and administrative backbone required to manage thousands of patient lives across multiple states.
- 2026 – The Premise-Crossover Merger: In February 2026, Premise Health completed a merger with Crossover Health. This transaction represents the "exit and re-entry" cycle in full effect. For many physicians and employers within these platforms, the change in ownership and the subsequent shift in corporate strategy occurred with little to no prior notice.
The Hidden Cost: Physician Turnover and the Exit Cycle
The most significant risk in the PE lifecycle is the period immediately following an exit. While the entry provides liquidity for physicians, the exit often triggers a talent drain. According to recent research on PE practice sales, physicians in PE-owned practices are 16.5 percentage points more likely to leave within two years of an exit compared to those in non-PE-owned practices.
The data is stark: two years post-sale, only 44% of physicians remain at PE-owned practices, whereas 60% remain at practices with no history of PE ownership. This turnover is often driven by the expiration of financial "golden handcuffs"—incentives designed to keep physicians in place during the initial hold period. When the PE firm exits and a new owner takes over, the original physicians, who may have already received their payout, often find the new corporate environment or increased productivity demands untenable.
In a model like DPC or Concierge medicine, where the primary "product" is the relationship between the doctor and the patient, high turnover is catastrophic. If the exit event predictably drives physician turnover, the very asset that commanded a premium multiple—the patient-physician continuity—is degraded the moment the sale is finalized.
Structural Nuance: The MDVIP Exception
Critics and proponents alike often point to MDVIP as a counter-narrative to the "buy-and-flip" reputation of private equity. MDVIP has held its position since 2014, far exceeding the typical three-to-five-year PE hold. However, the structural difference in their model is key. MDVIP operates as a network affiliation model rather than a direct acquisition platform.
In this model, physicians continue to own their practices but pay MDVIP for branding, infrastructure, and a referral system. Goldman Sachs and Charlesbank own the licensing company, not the physical clinics or the employment contracts of the doctors. This distinction has allowed MDVIP to scale without the immediate pressure to consolidate and flip a portfolio of owned assets. Nevertheless, the license company itself remains an asset built for an eventual sale. A long hold is not an absence of an exit; it is a delayed one. The question remains whether a future buyer will maintain the same hands-off approach or seek to extract more value through tighter operational control.
Implications for Operators and Investors
For healthcare operators building in the direct care space, the primary diligence question is no longer about the current owner’s promises of clinical autonomy. Instead, the focus must shift to the contractual and operational realities of the exit. Who absorbs the disruption when the platform is sold? What protections are in place for patients if their physician decides to leave following a change in ownership?
For investors, the underwriting of these deals must account for the "continuity risk." If a DPC platform’s valuation is based on a 90% patient retention rate, but that retention is tied to a specific physician who is likely to leave after the next recapitalization, the valuation is fundamentally flawed. The market has yet to price in the potential for a mass exodus of talent once the current wave of PE-backed platforms reaches the exit stage.
The Future of Independent Medicine under PE Ownership
The financial incentives for physicians to sell to private equity are rational. Selling a practice often allows a physician to convert years of future income into a lump sum taxed at a favorable capital gains rate. It provides an "off-ramp" for older physicians and a "growth engine" for younger ones who lack the capital to scale their own infrastructure.
However, the "growth is the thesis" mantra of private equity means that the speed of scaling often takes precedence over the preservation of the care model. As platforms like Premise, Frontier, and Revelstoke continue to expand, the pressure to maintain high EBITDA multiples will only increase.
The stage that will ultimately determine whether the DPC and Concierge models survive is the one currently being ignored: the exit. If the second and third generations of owners prioritize short-term margins over the long-term trust inherent in the direct care model, the "revolution" in primary care may end up looking remarkably like the fragmented, high-turnover system it sought to replace.
Conclusion: Pricing the Unpriced
The entry of capital into independent medicine is not inherently negative; practices require modern infrastructure and physicians deserve liquidity for the value they create. However, the industry is approaching a crossroads. The first wave of PE-backed DPC and Concierge investments is maturing. As these firms prepare for their second and third exits, the impact on physician retention and patient care will become impossible to ignore.
Stakeholders—including employers who contract with these platforms and patients who pay out-of-pocket memberships—must begin to demand transparency regarding ownership transitions. The survival of the direct care model depends on its ability to maintain continuity through cycles of corporate restructuring. Until the risks associated with the private equity exit are fully understood and priced, the stability of the most promising sector of American primary care remains in jeopardy.
